Clozapine vs Quetiapine (Seroquel XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)
Result source: NCT03510325
Quetiapine (Seroquel XR)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00640601 · Phase 3 · completed
This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Reported efficacy
Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) (not_applicable)
Result source: NCT00640601
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Clozapine | Quetiapine (Seroquel XR) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00649844 | -24 vs -15.9−8.1 vs placeboNCT018103801 other result
|
| CGI-S, change | —Not posted · NCT00649844 | -1.4 vs -0.9−0.5 vs placeboNCT018103801 other result
|
| PANSS response | —Not posted · NCT00649844 | 62.7% vs 32.1%+30.6 vs placeboNCT01810380 |
| PSP, change | —Not posted · NCT00649844 | 15.3 vs 9.4+5.9 vs placeboNCT01810380 |
| Relapse (% of patients) | —Not posted · NCT00649844 | —Not posted · NCT00159770 |
PANSS total, change
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel XR)
- -24 vs -15.9−8.1 vs placeboNCT01810380
1 other result
- 102.3 vs 100.5 NCT00640562
CGI-S, change
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel XR)
- -1.4 vs -0.9−0.5 vs placeboNCT01810380
1 other result
- -1.5 vs -1.0 NCT00640562
PANSS response
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel XR)
- 62.7% vs 32.1%+30.6 vs placeboNCT01810380
PSP, change
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel XR)
- 15.3 vs 9.4+5.9 vs placeboNCT01810380
Relapse (% of patients)
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel XR)
- —Not posted · NCT00159770
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clozapine: 3 of 4 rows · Quetiapine (Seroquel XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clozapine | Quetiapine (Seroquel XR) |
|---|---|---|
| Dropout rate | 41.7%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT00498550 · Phase 4 · registry result, not featured evidence 17.2% NCT02404155 · Phase na · registry result, not featured evidence | 38%a NCT00640601 · Phase 3 show 7 more results16.5% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 20% NCT00954122 · Phase 4 · registry result, not featured evidence 30.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 20.8%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results— NCT00498550 · Phase 4 · registry result, not featured evidence — NCT02404155 · Phase na · registry result, not featured evidence | 14.6%a NCT00640601 · Phase 3 show 7 more results7.3% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 4.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 2.6%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 13%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results26.7% NCT00498550 · Phase 4 · registry result, not featured evidence 6.9% NCT02404155 · Phase na · registry result, not featured evidence | 11.2%a NCT00640601 · Phase 3 show 7 more results3.7% NCT00640562 · Phase 3 0%Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence 0%Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 0% NCT00779506 · Phase 4 · registry result, not featured evidence 1.3%Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence —Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a other-sialorrhea 43.5% weight gain 30.4% sedation 21.7% NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more resultsgastrointestinal disorder - other: hypersalivation 66.7% somnolence 60% weight gain 40% NCT00498550 · Phase 4 · registry result, not featured evidence salivation 68.2% sedation 52.9% malaise 52.6% NCT02404155 · Phase na · registry result, not featured evidence | show 5 more resultssomnolence 3.2% delusion 1.6% dizziness 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence psychotic disorder 1.6% sedation 1.6% sleep disorder 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence constipation 25.5% insomnia 23.4% sedation 12.8% NCT00779506 · Phase 4 · registry result, not featured evidence somnolence 22.2% (placebo 5%) weight increased 13.1% (placebo 3.7%) dizziness 11.8% (placebo 0.6%) NCT01810380 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clozapine
Quetiapine (Seroquel XR)
show 2 more results
show 1 more result
show 1 more result
show 2 more results
show 1 more result
show 1 more result
+ 22 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Quetiapine (Seroquel XR)'s landscape